Ivarmacitinib clinical trials
Also written SHR0302.
How each study uses ivarmacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ivarmacitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
42 studies that test it; most in 2026 (12)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 19
Jiangsu HengRui Medicine Co., Ltd. (15) · Reistone Biopharma Company Limited (8) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Chinese SLE Treatment And Research Group (2) · Peking University Third Hospital (1) · Huijie Zhang (1) · Peking University People's Hospital (1) · Tongji Hospital (1)
Often tested with
Tested in the same studies.
Camrelizumab (2) · Celecoxib (1) · Immune checkpoint inhibitors (1) · HMPL-013 (1) · Antilymphocyte Serum (1) · Zeprumetostat (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test ivarmacitinib.
- Dec 2026A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched TransplantationPhase 1/2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLCPhase 2 · Chunxia Su
- Feb 2027Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaPhase 2 · Fudan University
- Mar 2027A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental VitiligoPhase 2 · Jiangsu HengRui Medicine Co., Ltd.
- Jun 2027Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World StudyNot applicable · Peking University People's Hospital
Studies
Open first, then newest update. How each study uses ivarmacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 42
- Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later TreatmentRecruitingPhase 2Renmin Hospital of Wuhan UniversityNCT07896096Written as Ivarmacitinib Sulfate Tablets
- Ivarmacitinib With or Without Celecoxib for Ankylosing SpondylitisNot yet recruitingPhase 4Peking University Third HospitalNCT07894497Written as Ivarmacitinib with celecoxib
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07505186Written as Ivarmacitinib
- JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1DNot yet recruitingPhase 2Huijie ZhangNCT07845955Written as Ivarmacitinib
- Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus ErythematosusNot yet recruitingPhase 2/3Chinese SLE Treatment And Research GroupNCT07814664Written as Ivarmacitinib Sulfate Tablets
- Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female DonorsRecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07570745Written as Low-dose ATG + PTCy + Ivarmacitinib
- Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World StudyNot yet recruitingNot applicablePeking University People's HospitalNCT07550452Written as Ivarmacitinib Sulfate Tablets
- Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaRecruitingPhase 2Fudan UniversityNCT06519526Written as SHR-0302
- Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingPhase 4Chinese SLE Treatment And Research GroupNCT07451665Written as Ivarmacitinib
- Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid ArthritisNot yet recruitingPhase 4Tongji HospitalNCT07452445Written as Ivarmacitinib
- A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental VitiligoRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07251595Written as SHR0302 Tablets
- A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched TransplantationNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07381114Written as Ivarmacitinib
- Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune IntoleranceNot yet recruitingPhase 2Fujian Cancer HospitalNCT07313202Written as Ivarmacitinib
- Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and AdultsNot yet recruitingNot applicableXiangya Hospital of Central South UniversityNCT07276620Written as Ivarmacitinib Sulfate Tablets
- A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar PustulosisRecruitingNot applicableXijing HospitalNCT07270003Written as Ivarmacitinib
- Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia RheumaticaNot yet recruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07266168Written as Ivarmacitinib tablet
- SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLCNot yet recruitingPhase 2Chunxia SuNCT06925048Written as PD-L1 inhibitor+SHR0302
- A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Reistone Biopharma Company LimitedNCT05181137Written as SHR0302
- Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingPhase 1Henan Cancer HospitalNCT05900089Written as SHR0302
- Ivarmacitinib for Refractory Behcet's SyndromeWithdrawnPhase 2Liu TianNCT07634848Written as Ivarmacitinib
See all 42 studies that test ivarmacitinib →
Given beside what is tested · 1 — ivarmacitinib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with ivarmacitinib
What changed recently
From the registry's own updates since Oct 17, 2026.
Newly registered2
Codes
What other systems call ivarmacitinib · ClinicalTrials.gg INT000650
- MeSH (NLM) C000615713ivarmacitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K6K4B9Z5TVIVARMACITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q123499437ivarmacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C186403IvarmacitinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615713 | ivarmacitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K6K4B9Z5TV | IVARMACITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123499437 | ivarmacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C186403 | Ivarmacitinib | One source FDA |
Also registered as ivarmacitinib sulfate (UNII CN7B3Z5G04).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.